摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-fluoro-5-methoxy-2-methylquinoline | 931413-59-1

中文名称
——
中文别名
——
英文名称
8-fluoro-5-methoxy-2-methylquinoline
英文别名
——
8-fluoro-5-methoxy-2-methylquinoline化学式
CAS
931413-59-1
化学式
C11H10FNO
mdl
——
分子量
191.205
InChiKey
UNPLQAGUEXIURZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    300.4±37.0 °C(Predicted)
  • 密度:
    1.185±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    8-fluoro-5-methoxy-2-methylquinolineN-ethyl-diisopropylethylamine三溴化硼potassium carbonate 作用下, 以 二氯甲烷异丙醇丁酮 为溶剂, 生成 6-[[1-[2-(8-fluoro-2-methylquinolin-5-yl)oxyethyl]piperidin-4-yl]methyl]-4H-1,4-benzoxazin-3-one
    参考文献:
    名称:
    3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors
    摘要:
    Investigation of halogen substitution in lead compound 1 has led to the identification of analogues which combine high affinity for 5-HT1A receptors and potent serotonin reuptake inhibitory activity. Several compounds show an improved selectivity over 5-HT1B and 5-HT1D receptors and a superior pharmacokinetic profile in the rat. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.11.031
  • 作为产物:
    参考文献:
    名称:
    3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors
    摘要:
    Investigation of halogen substitution in lead compound 1 has led to the identification of analogues which combine high affinity for 5-HT1A receptors and potent serotonin reuptake inhibitory activity. Several compounds show an improved selectivity over 5-HT1B and 5-HT1D receptors and a superior pharmacokinetic profile in the rat. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.11.031
  • 作为试剂:
    描述:
    2-氟-5-甲氧基苯胺 、 8-chloro-5-methoxy-2-methylquinoline hydrochloride 、 (2S)-5-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline 、 、 potassium carbonate8-fluoro-5-methoxy-2-methylquinoline二氯甲烷Sodium sulfate-III 、 silica gel 、 ethyl acetate-petroleum ether 作用下, 以 二氯甲烷 为溶剂, 以to afford 8-fluoro-5-methoxy-2-methylquinoline (25.2 g, 62%) as a yellow solid的产率得到8-fluoro-5-methoxy-2-methylquinoline
    参考文献:
    名称:
    Tetrahydroquinoline compositions as BET bromodomain inhibitors
    摘要:
    本发明涉及用于治疗癌症、炎症性疾病、糖尿病和肥胖症的溴和额外末端(BET)溴域抑制剂,具有公式I:其中W、X、Y、Z、R1、R2、R5和R8如本文所述。
    公开号:
    US09388161B2
点击查看最新优质反应信息

文献信息

  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    申请人:Forma Therapeutics, Inc.
    公开号:US20150232445A1
    公开(公告)日:2015-08-20
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R 1 , R 2 , R 5 , and R 8 are as described herein.
    本发明涉及抑制和额外末端(BET)域的抑制剂,其可用于治疗癌症、炎症性疾病、糖尿病和肥胖症,其化学式为I:其中W、X、Y、Z、R1、R2、R5和R8如本文所述。
  • TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS
    申请人:Forma Therapeutics, Inc.
    公开号:EP3799872A1
    公开(公告)日:2021-04-07
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    本发明涉及可用于治疗癌症、炎症性疾病、糖尿病和肥胖症的具有式 I 的外末端 (BET) odomains 抑制剂: 其中 W、X、Y、Z、R1、R2、R5 和 R8 如本文所述。
  • Tetrahydroquinoline compositions as bet bromodomain inhibitors
    申请人:FORMA Therapeutics, Inc.
    公开号:US10611750B2
    公开(公告)日:2020-04-07
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    本发明涉及可用于治疗癌症、炎症性疾病、糖尿病和肥胖症的具有式 I 的外末端 (BET) odomains 抑制剂: 其中 W、X、Y、Z、R1、R2、R5 和 R8 如本文所述。
  • [EN] TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS<br/>[FR] COMPOSITIONS DE TÉTRAHYDROQUINOLINE UTILISÉES COMME INHIBITEURS DE PROTÉINES À BROMODOMAINE ET DOMAINE EXTRATERMINAL (BET)
    申请人:BAIR KENNETH W
    公开号:WO2015074064A3
    公开(公告)日:2015-07-09
  • EP3071203B1
    申请人:——
    公开号:EP3071203B1
    公开(公告)日:2020-12-23
查看更多